EUCTR2004-000283-27-GB进行中（未招募）1 期
A Pilot Open-Label Study to Investigate the Safety and Anti-inflammatory Effects of VX-765, an Orally Administered Interleukin-1ß Converting Enzyme Inhibitor, in Patients with Muckle-Wells Syndrome
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Confirmed diagnosis of Muckle-Wells syndrome, as defined by mutations of the NALP3/CIAS1 gene, associated with laboratory evidence of acute phase response; symptoms of rash, conjunctivitis, fever, fatigue, or arthralgia; SAA greater than 10 mg/L on 2 consecutive occasions, patient agreement to discontinue anti-inflammatory medications.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy/lactation, any chronic inflammatory disorder other than Muckle-Wells Syndrome, medication that may alter drug absorption, recent use of other investigational drugs, recent blood/plasma donation, drug allergy/hypersensitivity
研究者
相似试验
已完成
不适用
A study to test the efficacy and safety of the Zip-stitch device in patients with minor lacerationsCTRI/2022/09/046040Simplified Healthcare Pvt Ltd
进行中（未招募）
不适用
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyEpilepsyEUCTR2014-004379-22-Outside-EU/EEACB BIOSCIENCES, Inc.45
进行中（未招募）
1 期
A phase 2a trial to evaluate the safety and tolerability of LUM001 in subjects with Primary Sclerosing Cholangitis (PSC) during 14 weeks of treatment.Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology.PSC is characterized by inflammation and fibrosis of the intra- and extrahepatic biliary tree resulting in diffuse multifocal stricture formation leading to biliary cirrhosis, portal hypertension and liver failure. PSC is a life-threatening and debilitating disease. The median survival from diagnosis in symptomatic patients with PSC has been estimated to be 12 years.MedDRA version: 17.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2014-005558-21-GBumena Pharmaceuticals LLC20
进行中（未招募）
1 期
A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 (bexmarilimab) in haematological malignancies in combination with azacitidine or azacitidine and venetoclax-Myelodysplastic Syndrome-Chronic Myelomonocytic Leukemia-Acute Myeloid LeukemiaMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-002104-12-FIFaron Pharmaceuticals Ltd.343
进行中（未招募）
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects with Advanced or Metastatic Solid TumorsAdvanced or metastatic solid tumors with KRASG12C mutationsAdvanced Solid Tumors, Metastatic Solid Tumors, KRASG12CJPRN-jRCT2031220006Kitano Tina12